Current Report Filing (8-k)
March 27 2017 - 11:50AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 23, 2017
KALVISTA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
|
|
001-36830
|
|
20-0915291
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
One Kendall Square
Building 200, Suite 2203
Cambridge, MA
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(857)
999-0075
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
On March 23, 2017, KalVista Pharmaceuticals,
Inc. (the Company) held a special meeting of its stockholders at which the Companys stockholders voted on the proposals set forth below. The final results regarding each proposal are set forth below.
Proposal No. 1: Approval of the 2017 Equity Incentive Plan:
|
|
|
|
|
|
|
Votes
Cast For
|
|
Votes
Cast
Against
|
|
Number of
Abstentions
|
|
Number of
Broker Non-Votes
|
7,232,865
|
|
110,262
|
|
943
|
|
0
|
Proposal No. 2: Approval of the 2017 Employee Stock Purchase Plan:
|
|
|
|
|
|
|
Votes
Cast For
|
|
Votes
Cast
Against
|
|
Number of
Abstentions
|
|
Number of
Broker Non-Votes
|
7,303,409
|
|
40,245
|
|
416
|
|
0
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
KALVISTA PHARMACEUTICALS, INC.
|
|
|
|
|
Date: March 27, 2017
|
|
|
|
By:
|
|
/s/ Benjamin L. Palleiko
|
|
|
|
|
|
|
Benjamin L. Palleiko
|
|
|
|
|
|
|
Chief Financial Officer
|
3
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Mar 2024 to Apr 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Apr 2023 to Apr 2024